The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.

Inclusion Criteria Concurrent Medication: Allowed: Vitamins if already being taken prior to start of therapy. Patients must have: Asymptomatic HIV infection. CD4 count between 300 and 650. Prior Medication: Required: AZT at doses between 500 and 1200 mg/day for at least 6 weeks prior to enrollment. Allowed: Aspirin, Tylenol, or ibuprofen up to 48 hours prior to start of therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Positive Hepatitis B surface antigen or clinical evidence of chronic active hepatitis of any type. Signs or symptoms of HIV infection including oral candidiasis, history of multidermatomal zoster, unexplained weight loss in excess of 10 percent body weight in the past 6 months, chronic diarrhea, or history of AIDS-defining opportunistic infections. Concurrent Medication: Excluded: Concomitant medications (other than AZT) for the 14 days prior to start of therapy. Patients with the following prior conditions are excluded: History of AZT intolerance including hematologic, hepatic, and/or neurologic toxicity. History of seizures. History of any antiepileptics within the past 10 years. History of abnormal bleeding or intrinsic or extrinsic coagulopathy. Signs or symptoms of HIV infection including oral candidiasis, history of multidermatomal zoster, unexplained weight loss in excess of 10 percent body weight in the past 6 months, chronic diarrhea, or history of AIDS-defining opportunistic infections. Prior Medication: Excluded: Antiepileptics within the past 10 years. Prior valproic acid. Concomitant medications (other than AZT) within 14 days of enrollment.